Pamela M Murnane1,2,3, Renate Strehlau3, Stephanie Shiau1,3,4, Faeezah Patel3, Ndileke Mbete3, Gillian Hunt5, Elaine J Abrams3,4,6,7, Ashraf Coovadia3, Louise Kuhn1,3,4. 1. Gertrude H. Sergievsky Center, College of Physicians and Surgeons, Columbia University, New York, New York. 2. Center for AIDS Prevention Studies, Department of Medicine, University of California, San Francisco. 3. Empilweni Services and Research Unit, Rahima Moosa Mother and Child Hospital, Department of Paediatrics and Child Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. 4. Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York. 5. Centre for HIV and STIs, National Institute for Communicable Diseases, Johannesburg, South Africa. 6. ICAP, Mailman School of Public Health. 7. Department of Pediatrics, College of Physicians & Surgeons, Columbia University, New York, New York.
Abstract
BACKGROUND: We previously demonstrated the noninferiority of switching to efavirenz (EFV) versus remaining on ritonavir-boosted lopinavir (LPV/r) for virologic control in children infected with human immunodeficiency virus (HIV) and exposed to nevirapine (NVP) for prevention of mother-to-child transmission. Here we assess outcomes up to 4 years post-randomization. METHODS: From 2010-2013, 298 NVP-exposed HIV-infected children ≥3 years of age were randomized to switch to EFV or remain on LPV/r in Johannesburg, South Africa (Clinicaltrials.gov NCT01146873). After trial completion, participants were invited to enroll into observational follow-up. We compared HIV RNA levels, CD4 counts and percentages, lipids, and growth across groups through four years post-randomization. RESULTS: HIV RNA levels 51-1000 copies/mL were less frequently observed in the EFV group than the LPV/r group (odds ratio [OR] 0.67, 95% confidence interval [CI]: 0.51-0.88, P = .004), as was HIV RNA >1000 copies/mL (OR 0.52 95% CI: 0.28-0.98, P = .04). The probability of confirmed HIV RNA >1000 copies/mL by 48 months was 0.07 and 0.12 in the EFV and LPV/r groups, respectively (P = .21). Children randomized to EFV had a reduced risk of elevated total cholesterol (OR 0.45 95% CI: 0.27-0.75, P = .002) and a reduced risk of abnormal triglycerides (OR 0.42, 95% CI 0.29-0.62, P < .001). CONCLUSIONS: Our results indicate that the benefits of switching virologically suppressed NVP-exposed HIV-infected children ≥3 years of age from LPV/r to EFV are sustained long-term. This approach has several advantages, including improved palatability, reduced metabolic toxicity, simplified cotreatment for tuberculosis, and preservation of second line options. CLINICAL TRIALS REGISTRATION: NCT01146873.
BACKGROUND: We previously demonstrated the noninferiority of switching to efavirenz (EFV) versus remaining on ritonavir-boosted lopinavir (LPV/r) for virologic control in children infected with human immunodeficiency virus (HIV) and exposed to nevirapine (NVP) for prevention of mother-to-child transmission. Here we assess outcomes up to 4 years post-randomization. METHODS: From 2010-2013, 298 NVP-exposed HIV-infected children ≥3 years of age were randomized to switch to EFV or remain on LPV/r in Johannesburg, South Africa (Clinicaltrials.gov NCT01146873). After trial completion, participants were invited to enroll into observational follow-up. We compared HIV RNA levels, CD4 counts and percentages, lipids, and growth across groups through four years post-randomization. RESULTS: HIV RNA levels 51-1000 copies/mL were less frequently observed in the EFV group than the LPV/r group (odds ratio [OR] 0.67, 95% confidence interval [CI]: 0.51-0.88, P = .004), as was HIV RNA >1000 copies/mL (OR 0.52 95% CI: 0.28-0.98, P = .04). The probability of confirmed HIV RNA >1000 copies/mL by 48 months was 0.07 and 0.12 in the EFV and LPV/r groups, respectively (P = .21). Children randomized to EFV had a reduced risk of elevated total cholesterol (OR 0.45 95% CI: 0.27-0.75, P = .002) and a reduced risk of abnormal triglycerides (OR 0.42, 95% CI 0.29-0.62, P < .001). CONCLUSIONS: Our results indicate that the benefits of switching virologically suppressed NVP-exposed HIV-infected children ≥3 years of age from LPV/r to EFV are sustained long-term. This approach has several advantages, including improved palatability, reduced metabolic toxicity, simplified cotreatment for tuberculosis, and preservation of second line options. CLINICAL TRIALS REGISTRATION: NCT01146873.
Authors: S H Eshleman; M Mracna; L A Guay; M Deseyve; S Cunningham; M Mirochnick; P Musoke; T Fleming; M Glenn Fowler; L M Mofenson; F Mmiro; J B Jackson Journal: AIDS Date: 2001-10-19 Impact factor: 4.177
Authors: Rubeena Ramjan; Alexandra Calmy; Marco Vitoria; Edward J Mills; Andrew Hill; Graham Cooke; Nathan Ford Journal: Trop Med Int Health Date: 2014-03-17 Impact factor: 2.622
Authors: Stephanie Shiau; Stephen M Arpadi; Megan Burke; Afaaf Liberty; Cara Thurman; Faeezah Patel; Renate Strehlau; Elaine J Abrams; Ashraf Coovadia; Avy Violari; Louise Kuhn Journal: AIDS Care Date: 2019-07-09
Authors: Sophie Desmonde; Simone C Frank; Ashraf Coovadia; Désiré L Dahourou; Taige Hou; Elaine J Abrams; Madeleine Amorissani-Folquet; Rochelle P Walensky; Renate Strehlau; Martina Penazzato; Kenneth A Freedberg; Louise Kuhn; Valeriane Leroy; Andrea L Ciaranello Journal: Open Forum Infect Dis Date: 2019-06-11 Impact factor: 3.835